Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Mike Frick"'
Autor:
Gisa Dang, Mike Frick
Publikováno v:
Frontiers in Sociology, Vol 8 (2023)
Externí odkaz:
https://doaj.org/article/ec42a6e4353a43d28df0deefa34e7ae8
Autor:
Alberto L. Garcia-Basteiro, Richard G. White, Dereck Tait, Alexander C. Schmidt, Molebogeng X. Rangaka, Matthew Quaife, Elisa Nemes, Robin Mogg, Philip C. Hill, Rebecca C. Harris, Willem A. Hanekom, Mike Frick, Andrew Fiore-Gartland, Tom Evans, Alemnew F. Dagnew, Gavin Churchyard, Frank Cobelens, Marcel A. Behr, Mark Hatherill
Publikováno v:
European Respiratory Review, Vol 31, Iss 164 (2022)
Tuberculosis (TB) remains a leading infectious cause of death worldwide and the coronavirus disease 2019 pandemic has negatively impacted the global TB burden of disease indicators. If the targets of TB mortality and incidence reduction set by the in
Externí odkaz:
https://doaj.org/article/87396fc05bac435a828bd8864008890f
Publikováno v:
PLoS ONE, Vol 17, Iss 7 (2022)
Background Tuberculosis (TB), human immunodeficiency virus (HIV), and hepatitis C virus (HCV) share a global presence and propensity to disproportionately affect marginalized populations. However, over recent decades, many fewer drugs have been broug
Externí odkaz:
https://doaj.org/article/13cbb4bee4554e8dbd100a86aa6ebc2d
Publikováno v:
PLoS ONE, Vol 15, Iss 9, p e0239118 (2020)
IntroductionIn 2012, bedaquiline became the first new treatment from a novel class to be approved for tuberculosis in nearly five decades and is now a core component of the standard of care for multidrug-resistant tuberculosis. In addition to the ori
Externí odkaz:
https://doaj.org/article/57e527eba55f49ec85008e6438710e53
Autor:
Mike Frick
Publikováno v:
International Journal of Infectious Diseases, Vol 56, Iss C, Pp 21-24 (2017)
Tuberculosis (TB) killed more people in 2015 than any other single infectious agent, but funding for research to develop better prevention, diagnosis, and treatment methods for TB declined to its lowest level in 7 years. TB research and development (
Externí odkaz:
https://doaj.org/article/888fc650f3ec445abe86ecc3c665e346
Autor:
Molebogeng X Rangaka, Mike Frick, Gavin Churchyard, Alberto L García-Basteiro, Mark Hatherill, Willem Hanekom, Philip C Hill, Yohhei Hamada, Matthew Quaife, Johan Vekemans, Richard G White, Frank Cobelens
Publikováno v:
The Lancet Respiratory Medicine. 11:380-390
Approximately 10·6 million people worldwide develop tuberculosis each year, representing a failure in epidemic control that is accentuated by the absence of effective vaccines to prevent infection or disease in adolescents and adults. Without effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37379fbaadf1e7c9a74fee7b8f136348
https://doi.org/10.1016/s2213-2600(23)00084-x
https://doi.org/10.1016/s2213-2600(23)00084-x
Autor:
Maurine D. Miner, Mark Hatherill, Vidya Mave, Judith Currier, Joseph Eron, Glenda E. Gray, Sharon Nachman, Peter Kim, Sarah Read, Richard White, Anneke Hessling, Frank Cobelens, Sheral Patel, Mike Frick, Theodore Bailey, Robert Seder, Joanne Flynn, Jyothi Rengarajan, Deepak Kaushal, Willem Hanekom, Alexander Schmidt, Thomas Scriba, Elisa Nemes, Erica Andersen-Nissen, Alan Landay, Susan Dorman, Grace Aldrovandi, Lisa M. Cranmer, Cheryl Day, Lele Rangaka, Alberto Garcia-Basteiro, Andrew Fiore-Gartland, Robin Mogg, James G. Kublin, Amita Gupta, Gavin Churchyard
Many new TB vaccine candidates in the development pipeline need to be studied in people with HIV. People with HIV are at high risk of developing Mycobacterium tuberculosis (Mtb) infection and TB disease and tend to develop less robust vaccine induced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76fb3a5fd77fda8454cbd2bdd99aa27b
https://doi.org/10.21203/rs.3.rs-1605760/v1
https://doi.org/10.21203/rs.3.rs-1605760/v1
Autor:
Maurine D Miner, Mark Hatherill, Vidya Mave, Glenda E Gray, Sharon Nachman, Sarah W Read, Richard G White, Anneke Hesseling, Frank Cobelens, Sheral Patel, Mike Frick, Theodore Bailey, Robert Seder, Joanne Flynn, Jyothi Rengarajan, Deepak Kaushal, Willem Hanekom, Alexander C Schmidt, Thomas J Scriba, Elisa Nemes, Erica Andersen-Nissen, Alan Landay, Susan E Dorman, Grace Aldrovandi, Lisa M Cranmer, Cheryl L Day, Alberto L Garcia-Basteiro, Andrew Fiore-Gartland, Robin Mogg, James G Kublin, Amita Gupta, Gavin Churchyard
Publikováno v:
The lancet. HIV. 9(11)
New tuberculosis vaccine candidates that are in the development pipeline need to be studied in people with HIV, who are at high risk of acquiring Mycobacterium tuberculosis infection and tuberculosis disease and tend to develop less robust vaccine-in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90d26ce98f9fb2a6dfce9deddf9930fd
https://pubmed.ncbi.nlm.nih.gov/36372080
https://pubmed.ncbi.nlm.nih.gov/36372080
Publikováno v:
The International Journal of Tuberculosis and Lung Disease. 24:48-56
Until recently, human rights have played a minor role in the fight against tuberculosis (TB), even less so in TB research. This is changing, however. The WHO's End TB Strategy and Ethics Guidance stress respect for human rights and ethical principles
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b240324bef1ba6861c53d0b186cbd7bd
https://doi.org/10.5588/ijtld.17.0897
https://doi.org/10.5588/ijtld.17.0897
Autor:
Gisa Dang, Mike Frick
Publikováno v:
The Right to Science
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20d6145e89b5ef03a142820f26c7adfa
https://doi.org/10.1017/9781108776301.016
https://doi.org/10.1017/9781108776301.016